Factors predicting long-term survival in low-risk XXXX .

@entity1 @entity1892 @entity4349
The International Prognostic Index (IPI) is widely used for risk stratification of @entity1 with @entity1892 ( @entity1892 ). However, even among @entity1 with low-risk disease, according to the IPI a substantial proportion of @entity1 ultimately succumb to their disease. Using mature population-based data from the Danish Lymphoma Group, we analyzed if prognostic clinical pretreatment factors could be identified in @entity1 with low-risk @entity1892 . One hundred seventy-seven @entity1 , all with a prognostic profile as favorable as possible according to the IPI and treated with @entity4349 -based combination chemotherapy (92%) or loco-regional radiotherapy/surgery (8%) with curative intent were included. The median age was 50 years and 170 achieved complete remission. The median follow-up time was 11 years. Twenty-six @entity1 relapsed, with a median time to relapse of 12.1 months. Overall survival at 5 years and 10 years was 85% and 75%, respectively. Stage II was associated with poor response to treatment (P=0.044). In a multivariate analysis, Stage II (P=0.001) and age >50 years (P=0.043) were independently associated with poor outcome. @entity1 without these adverse factors had an excellent prognosis, with a survival at 5 and 15 years of 90% and 80%, respectively. In contrast, @entity1 with both adverse factors had poor outcome, with survival at 5 and 15 years of 70% and 29%, respectively (P<0.001). The present data suggest that risk stratification of @entity1892 @entity1 with a favorable IPI score can be improved by the simple use of two clinical pretreatment factors.
